PDS Biotechnology Corp Files 8-K

TL;DR

PDS Biotechnology filed an 8-K on 9/16/24 covering Reg FD, other events, and financials.

AI Summary

PDS Biotechnology Corporation filed an 8-K on September 16, 2024, to report on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, incorporated in Delaware, is located at 303A College Road East, Princeton, NJ 08540.

Why It Matters

This 8-K filing provides updates on company events and financial information, which are crucial for investors to assess the current status and potential future performance of PDS Biotechnology Corp.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not contain specific material events that would inherently increase risk.

Key Numbers

• 001-37568 — SEC File Number (Identifies the company's filing history with the SEC.)
• 26-4231384 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• PDS Biotechnology Corporation (company) — Registrant
• September 16, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 303A College Road East, Princeton, NJ 08540 (address) — Principal Executive Offices
• Edge Therapeutics, Inc. (company) — Former Company Name

FAQ

Key Financial Figures

• $0.00033 — h registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Stock Mar

Filing Documents

• ef20035887_8k.htm (8-K) — 29KB
• ef20035887_ex99-1.htm (EX-99.1) — 25KB
• image00001.jpg (GRAPHIC) — 3KB
• 0001140361-24-041102.txt ( ) — 198KB
• pdsb-20240916.xsd (EX-101.SCH) — 4KB
• pdsb-20240916_lab.xml (EX-101.LAB) — 21KB
• pdsb-20240916_pre.xml (EX-101.PRE) — 16KB
• ef20035887_8k_htm.xml (XML) — 4KB

01

Item 7.01 Regulation FD Disclosure. On September 16, 2024, PDS Biotechnology Corporation (the "Company") issued a press release announcing that updated data from the ongoing VERSATILE-002 trial evaluating Versamune HPV (formerly PDS0101) in combination with KEYTRUDA (pembrolizumab) as a first-line (1L) treatment for patients with HPV16-positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) was featured in a poster ( 879P ) presented on September 14, 2024 at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. .

01

Item 8.01 Other Events. The information set forth in the press release referred to in Item 7.01 above, other than the third and fifth paragraphs thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated September 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: September 16, 2024 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR